drugset / Trial / NCT05822037
CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Unknown
6 enrolled
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia
Timeline
- Start
- 2023-04-12
- Primary completion
- 2026-04-29
- Completion
- 2026-04-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT0594CP | Cell therapy | — | — |